Table 2.

Immunophenotypic and genetic characteristics of 433 cases of de novo DLBCL with regard to phosphorylated STAT3 expression

	Overall (%)	pSTAT3+ (%)	pSTAT3− (%)	P value
MYC expression	260/398 (65)	61/65 (94)	199/333 (60)	<0.001
BCL2 expression	192/398 (48)	35/66 (53)	157/332(47)	0.420
MYC/BCL2 co-expression	130/396 (33)	34/65 (52)	96/331 (29)	0.001
BCL2 rearranged	69/378 (18)	7/59 (12)	62/319 (19)	0.201
BCL6 rearranged	107/321 (33)	20/50 (40)	87/271 (32)	0.327
MYC rearranged	35/382 (9)	4/62 (6)	31/320 (10)	0.630
Double hit*	13/287 (5)	1/42 (2)	12/245 (5)	0.700
TP53 deletion	47/402 (12)	5/67 (7)	42/335 (13)	0.300
TP53 mutated	91/408 (22)	13/67 (19)	78/341 (23)	0.631
p53 expression	140/395 (36)	27/66 (41)	113/329 (34)	0.326
p50 expression	154/428 (36)	27/70 (39)	127/358 (35)	0.683
p52 expression	119/422 (28)	27/71 (38)	92/351 (26)	0.050
p65 expression	144/428 (34)	27/71 (38)	117/357 (33)	0.411
cRel expression	99/422 (24)	13/67 (19)	86/355 (24)	0.436
p50/p65 co-expression	77/422 (18)	14/70 (20)	63/352 (18)	0.735
p50/cRel co-expression	47/420 (11)	6/67 (9)	41/353 (12)	0.674
p52/p65 co-expression	41/414 (10)	11/70 (16)	30/344 (9)	0.081
p52/cRel co-expression	44/406 (11)	6/66 (9)	38/340 (11)	0.829
Classical NF-κB expression	100/427 (23)	15/70 (21)	85/357 (24)	0.758
Alternative NF-κB expression	71/417 (17)	12/70 (17)	59/347 (17)	1.000
NF-kB expression**	134/417 (32)	20/69 (29)	114/348 (33)	0.575
CD30 expression	72/439 (16)	12/72 (17)	60/367 (16)	1.000
pAKT expression	76/435 (17)	17/71 (24)	59/364 (16)	0.125
Cyclin D1 expression	10/432 (2)	2/71 (3)	8/361 (2)	0.672

pSTAT3, phosphorylated STAT3

^*double hit, MYC and BCL2 or BCL6 rearrangements

^**Summation of the classical and alternative NF-κB pathway expression